Northern Light

Many organizations consider themselves AI-ready.

But when it comes to delivering consistent, decision-ready insights, common gaps still surface:
• Fragmented intelligence across systems
• Limited trust in AI outputs
• Delays in getting insights to decision-makers
• Little visibility into research ROI

This blog outlines 6 signals that highlight where intelligence strategies fall short—and how to strengthen them.

A useful benchmark for any team evaluating AI maturity this year.

Read the full blog: https://www.northernlight.com/blog/6-signals-your-intelligence-strategy-isnt-ai-ready-and-how-to-fix-it?utm_source=FB&utm_medium=content&utm_campaign=6+signs

Generative AI is everywhere in competitive intelligence right now yet most teams are still stuck in pilot mode.

The gap often shows up in ex*****on:
• Outputs that lack traceability
• Workflows that aren’t fully integrated
• Limited trust from stakeholders

This post outlines how leading enterprises are operationalizing GenAI in CI—grounding outputs in trusted content, embedding AI into workflows, and delivering intelligence at the speed of decision-making.

Read the full blog: https://www.northernlight.com/blog/how-to-operationalize-generative-ai-in-competitive-intelligence?utm_source=meta&utm_medium=content&utm_campaign=blog

Most enterprise AI strategies start with the wrong question: build vs. buy.

But model choice isn’t what determines success.

What actually matters is whether your organization has the governed, scalable foundation required to make AI outputs trusted, usable, and decision-ready. Without it, even the most advanced models stall before delivering real value.

If AI is a priority this year, this is the layer most teams are missing.

👉 Read the full blog: https://www.northernlight.com/blog/build-vs-buy-is-the-wrong-question-what-enterprise-ai-actually-requires?utm_source=FB&utm_medium=content&utm_campaign=build+vs+buy

What does modern CI actually look like in life sciences?

It’s not more dashboards or data sources.

It’s the ability to deliver trusted, decision-ready insight—fast enough to matter.

In this session, we show how leading pharma teams are:
→ Moving from reactive reporting to continuous intelligence
→ Embedding AI without sacrificing trust or compliance
→ Delivering insights that leadership actually relies on

🎥 Watch the full webinar: https://www.northernlight.com/from-scientific-noise-to-strategic-insight

From Scientific Noise to Strategic Insight: Building a Modern Competitive & Market Intelligence Function in Life Sciences In this webinar, we explore how leading life sciences organizations are modernizing Competitive & Market Intelligence to support faster and more confident portfolio and commercialization decisions.

Most AI in financial services never makes it past pilot.

Not because of use cases. Because of governance.

No governance means no trust, no scale, no decisions.

The firms moving fastest have solved for all three.

Read the full blog: https://www.northernlight.com/blog/7-ways-ai-governance-accelerates-innovation-in-financial-services?utm_source=FB&utm_medium=content&utm_campaign=blog

Missed yesterday’s webinar? We've got you covered.

One takeaway stood out: The gap between signal and decision is where CI teams are losing ground.

It’s not a lack of data, but it’s how long it takes to connect it, validate it, and deliver it in a usable way.

In life sciences, that delay impacts everything from pipeline strategy to market access decisions.

Uncover what leading teams are doing differently. Read the recap: https://www.northernlight.com/blog/webinar-recap-from-scientific-noise-to-strategic-insight?utm_source=FB&utm_medium=content&utm_campaign=Webinar+Recap

Last chance: How leading pharma CI teams are modernizing intelligence to move faster.

Competitive intelligence in life sciences is becoming more complex.

But leading CI teams aren’t adding more manual work—they’re transforming how intelligence is gathered, connected, and delivered.

One of the biggest shifts? Moving from fragmented tools and siloed data to a centralized, decision-ready intelligence approach.

Join this week’s webinar with Sheri Larsen, Chief Product Officer, and Sarah Hughes, VP of Marketing, to see how Life Sciences organizations are upgrading their CI capabilities across R&D and Commercial.

🔗 Save your seat: https://app.livestorm.co/p/dbdfc3e7-4706-4b7a-9bf5-705b418e7146

Competitive Intelligence teams are being asked to track:
• clinical trials
• competitor pipelines
• regulatory signals
• market research
• conference insights

But many teams still rely on manual workflows and fragmented systems.

In our upcoming webinar, we explore how life sciences organizations are modernizing Competitive & Market Intelligence to support faster strategic decisions.

👉 Save your seat: https://app.livestorm.co/p/dbdfc3e7-4706-4b7a-9bf5-705b418e7146

The most important signals in pharma often appear years before products reach the market.

They show up in scientific abstracts, patent filings, and early research—not earnings calls.

Our latest blog explores why life sciences intelligence and early signal detection are becoming essential for pharma competitive intelligence and R&D foresight.

👉 Read the blog: https://www.northernlight.com/blog/what-is-life-sciences-intelligence--and-why-early-signals-matter-more-than-ever?utm_source=meta&utm_medium=social&utm_campaign=march+post

Life sciences organizations are facing three major pressures in 2026:
- Shifting disease risk pools
- Operating margin pressure across healthcare systems
- New pharmaceutical access models

These forces are changing how companies shape portfolios and launch therapies.

Competitive and Market Intelligence teams are increasingly responsible for synthesizing these signals into strategic insight.

Join our upcoming webinar to learn how CI leaders are modernizing intelligence capabilities across R&D and Commercial.

👉 Register here: https://app.livestorm.co/p/dbdfc3e7-4706-4b7a-9bf5-705b418e7146